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Myocarditis 
Definition 
 Myocarditis is an inflammatory disease of 
the heart muscle, diagnosed by 
established histological, immunological, 
and immunohistochemical criteria (the World 
Health Organization/International Society and Federation of Cardiology, 
1995) 
 
Epidemiology 
 The true incidence of myocarditis is unknown  
because the majority of cases are asymptomatic  
 Involvement of the myocardium has been 
reported in 1 to 5 % of patients with acute viral 
infections  
 Autopsy studies have revealed varying estimates  
of the incidence of myocarditis.  
 A 5% prevalence of active myocarditis was 
reported in a high-risk group of 186 sudden, 
unexpected medical deaths in children  
RISK FACTORS  
 
 Certain groups appear to be at 
increased risk of virus-induced 
myocarditis, and the course may be  
hyperacute  
• Young males  
• pregnant women  
• children (particularly neonates)  
• immunocompromised patients (HIV) 
Etiology of Myocarditis 
 Infection 
• Viral (most frequently identified viruses were  
enteroviruses (including coxsackievirus) until  
the 1990s, but now parvovius B19 and Human Herpes 
Virus 6 are more common)  
•  Bacterial, rickettsial, spirochetal 
• Protozoal 
• Fungal 
 Autoimmune disorders (celiac disease, systemic 
lupus erythematosus, Wegeners granulomatosis, 
giant cell arteritis, Kawasakis, and Takayasu 
arteritis)  
 Drugs (antibiotics, sulfonamides,  smallpox 
vaccine, tetanus toxoid, tricyclic 
antidepressants) 
 Toxins (Cocaine, phenytoin, ethanol) 
 Parasites Chagas, Toxoplasmosis, Trichinosis 
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Pathophysiology of viral myocarditis: after viral entry, virus replication leads to 
acute injury of the myocytes (acute myocarditis) and to activation of the host's 
immune system (subacute myocarditis). IFN = interferon; IL = interleukin; TNF = 
tumor necrosis factor 
Pathophysiology of Viral Myocarditis 
Time course of viral myocarditis in 3 phases (derived from murine 
models). The acute phase of myocarditis takes only a few days, 
whereas  the subacute and chronic phase covers a few weeks to 
several months. J Am Coll Cardiol. 2012;59(9):779-792. doi:10.1016/j.jacc.2011.09.074 
Time Course of Viral Myocarditis 
Clinical presentation 
Myocarditis is preceded by  
• flu-like symptoms (chills, fever, headache, muscle aches, 
general malaise)  
• gastrointestinal symptoms (decreased appetite, nausea, 
vomiting, and diarrhea 
Cardiac manifestations of myocarditis appear a few 
hours to a few days after the initial signs and 
symptoms. 
Cardiac symptoms consist of  
• symptoms of heart failure,  
• chest pain due to pericardial irritation 
• symptoms associated with heart block and arrhythmia.  
The possibility of myocarditis must be considered if a 
patient with cardiac symptoms is febrile. 
Clinical features 
 A variety of cardiac symptoms can be induced by 
myocarditis  
 Chest pain may occur, usually due to concomitant 
pericarditis  
 Excessive fatigue or decreased exercise ability may 
be the initial sign of myocardial dysfunction 
 Since both ventricles are generally involved, patients 
develop biventricular failure  
 Patients present with signs of right ventricular failure 
such as increased jvp, hepatomegaly, and peripheral 
edema  
 If there is predominant left ventricular involvement, 
the patient may present with the symptoms of 
pulmonary congestion dyspnea, orthopnea, rales, 
and, in severe cases, acute pulmonary edema 
Physical examination  
 
 In addition to the signs of fluid overload, the  
physical examination often reveals direct  
evidence of cardiac dysfunction in symptomatic  
patients  
 S3 and S4 gallops are important signs of 
impaired ventricular function  
 If the right or left ventricular dilatation is  
severe, auscultation may reveal murmurs of  
functional mitral or tricuspid insufficiency  
 A pericardial friction rub and effusion may  
become evident in patients with myopericarditis  
Blood studies 
 Erythrocyte sedimentation rate  elevation  - 60% 
 White cell count elevation - 25% 
 
Blood Biochemistry 
 
Transient elevation of: 
 C-reactive protein (CRP) 
 aspartate aminotransferase (AST) 
 lactate dehydrogenase (LDH) 
  the MB form creatine kinase (CK-MB) 
 cardiac troponin T  
Viral titers  
 
 Elevation of viral titer in a sample collected in the 
acute phase to at least four times that in a 
sample obtained in remission is useful for identify 
viral infection as the cause. 
 Acute and convalescent antibody titers may 
indicate an active or recent viral infection  
 They do not necessarily indicate the etiology of 
the cardiac abnormalities (most viruses involved 
in the pathogenesis of myocarditis are highly 
prevalent in the population - 70% of the 
population in Germany have been tested 
seropositive for PVB19 Jg G antibodies) 
Polymerase chain reaction 
 used to demonstrate the presence of 
viral infection and to detect the viral 
genome.  
Separation of virus in pericardial 
effusion or cardiac muscle tissue 
provides direct evidence of 
myocarditis 
Chest X-Ray 
 
 ranges from normal to  
 cardiac enlargement - the cardiac 
silhouette may also be globular when 
a pericardial effusion is present  
 pulmonary congestion 
Electrocardiography (I) 
 
 a sensitive and convenient means of 
diagnosis of myocarditis 
 must be timely repeated, since minor 
abnormalities in the ECG detected 
initially may become clearer over time 
 continuous ECG monitoring is crucial 
to detect potentially fatal arrhythmias 
 May be normal or abnormal 
 
 However, the abnormalities are nonspecific unless there is 
pericardial involvement (myocardial infarction pattern) 
 
 The changes that may be seen include 
• sinus tachycardia is most common 
• nonspecific ST –T abnormalities 
• supraventricular and ventricular arrhythmias 
• conduction blocks 
• a gradual increase in the width of the QRS complex is a 
sign of exacerbation of myocarditis. 
Electrocardiography (II) 
 
Myocarditis 
Echocardiography 
 Useful tool in managing patients with 
acute myocarditis 
• LV systolic dysfunction is common with 
segmental wall motion abnormalities/ 
global dysfunction 
• LV size is typically normal or mildly 
dilated 
• wall thickness may be increased 
• pericardial effusion 
• ventricular thrombi may be detected 
 
Magnetic resonance imaging 
 
 Contrast-enhanced MRI, using 
gadopentate dimeglumine which 
accumulates in inflammatory lesions, 
can detect the degree and extent of 
inflammation  
 The extent of relative myocardial 
enhancement correlates with clinical 
status and left ventricular function 
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(A) Long-axis and (B) short-axis T2-weighted edema images demonstrating focal 
myocardial edema in the subepicardium of the left midventricular lateral wall (red arrows). 
Corresponding (C) long-axis and (D) short-axis T1-weighted late gadolinium enhancement 
images demonstrate presence of typical late gadolinium enhancement in the  
subepicardium of the left midventricular lateral wall and the basal septum (red arrows). 
MRI Findings in Patients With Myocarditis 
Endomyocardial biopsy (EMB) 
 The gold standard in diagnosis of 
myocarditis - the definitive diagnosis 
of myocarditis can be made only by 
EMB  
 A negative EMB does not rule out 
focal myocarditis because of 
sampling error. This problem is 
minimized by multiple biopsies  
Endomyocardial Biopsy (EMB) 
 RV bioptome permit repetitive 
sampling 
 biopsy should be applied early 
after onset of symptoms to 
maximize yield - resolution may 
be seen in four days on serial 
biopsies 
EMB: DALLAS CRITERIA DX OF 
MYOCARDITIS 
 
 Introduced in 1986 for dx of pericardits  
 Based on endomyocardial biopsy specimens  
 Active Myocarditis if light microscopy 
revealed  infiltrating lymphocytes and 
myocytolysis 
 Borderline or on going myocardits if 
lymphocyte  infiltration and NO myocytolysis  
 Negative for Myocarditis if no lymphocytic 
infiltrate and no myocytolysis 
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(A, B) acute myocarditis -  
numerous necrotic myocytes 
(A, arrows) are associated 
with mononuclear cell 
infiltrates 
 
 
(C, D) chronic myocarditis - 
inflammatory cells are mainly 
present in areas with fibrosis 
(C, blue staining).  
Histopathological Findings in Hearts of Patients With 
Myocarditis 
Relation to the etiological factor :previous  infection, 
proven by clinical and laboratory data (pathogen 
isolation , immunological tests); allergy, exposure 
to chemical or physical factors  
+ 
Signs of myocardial lesion: 
Major criteria 
Minor criteria 
 
Diagnosis of myocarditis is considered in the 
presence of etiological factors AND the presence of 
2 major OR 1 major and 2 minor criteria 
Сlinical criteria of myocarditis 
proposed by New York Heart 
Association (1964; 1973 years) 
Signs of myocardial lesion: 
 
Major criteria 
 ECG changes  
 Elevated levels of cardioselective enzymes and 
proteins (CPK, CPK-MB, troponin T) 
 Heart enlargement (X-ray, ultrasound) 
 Heart failure 
 Cardiogenic shock 
Minor criteria 
 Tachycardia (sometimes bradycardia) 
 Weakening of Ist tone while auscultation 
 Gallop  
 
- mostly focal myocarditis 
- without heart enlargement  
- without heart failure – may be LV 
disfunction (HF 0-1 stage) 
- no life-threatening cardiac arrhythmias 
and conduction disorders 
- only nonspecific ECG changes 
(nonspecific ST-T abnormalities) and 
tachycardia.  
 
 
Severity of myocarditis: mild 
 focal or diffuse myocarditis  
 enlargement of heart cavities 
(relative valvular insufficiency) 
 moderate heart failure (stage I-IIA) 
 involment of pericardium 
(myopericarditis) 
 no life-threatening cardiac 
arrhythmias and conduction 
disorders 
Severity of myocarditis: 
moderate 
Myocarditis (1): AV block 2:1; Т-
wave inversion 
 
Myocarditis (2) : the same patient 
after treatment 
 
Myopericarditis 
Clinical Features 
 Most common-sudden or gradual onset 
of sharp or stabbing pain with radiation 
to back, neck, L shoulder or arm 
 Radiation to L trapezial ridge is 
distinguishing 
 Pain more severe with lying supine and 
relieved with sitting 
 Low grade fever, dyspnea and 
dysphagia 
 Transient, intermittent friction rub 
ECG changes in myopericarditis 
 
EKG-changes in four stages 
1-ST elevation in I, V5 and V6, PR 
depression in II, aVF and V4-V6 
2-ST segment normalizes, T wave decreases 
3-Inverted T waves in leads with previous 
ST elevation 
4-Return to normal ECG 
In I, V5, or V6 ST:Twave ratio >0.25 most 
likely acute pericarditis 
PQ-depression 
Myocarditis with pericardium involvement 
(myopericarditis): ST-segment elevation 
and PQ-segment depression 
 predominantly diffuse myocarditis with 
cardiomegaly, significant heart failure (II A-
B stage)  with  life-threatening disorders of 
cardiac rhythm and conduction.  
Severity of myocarditis: severe 
Natural History of Acute (Viral) 
Myocarditis 
Subclinical, no sequelae 
Fulminant; cardiac dilatation, heart 
failure, arrhythmias, death 
Self limited cardiac dysfunction 
with resolution in weeks/months 
Chronic cardiomyopathy 
Clinical course and Natural History  of 
Acute (Viral) Myocarditis 
1) acute  
2) subacute  
3) chronic  
4) myocardiofibrosis 
Classification of myocarditis : 
Stage 
 
 
1) with established etiology 
(infectious, bacterial, viral, 
parasitical, other diseases ) 
 2) with unspecified etiology  
 
Classification of myocarditis : 
Etiology 
 
1) lymphocytic; 
2) eosinophilic; 
3) giant cell; 
4) granulomatous  
Classification of myocarditis : 
Morphological features of infiltration 
(data EMB) 
Classification of myocarditis : 
Spreading 
1)focal  
2) diffuse  
1) mild 
2) moderate 
3) severe 
 
 
Classification of myocarditis : 
severity 
Classification of myocarditis 
VI. Complications: Cardiac rhythm and 
conduction abnormalities, 
thromboembolism, and others. 
VII. Heart failure: stage 0-III, I-IV FC.  
Treatment: etiotropic treatment  
 Antibiotic therapy – only after the confirmation of 
the etiological factor (diphtheria) 
  Antiviral drugs – only for proven viral 
myocarditis (etiologic agent is known AND 
sensitive to antiviral drug) 
 However,  beneficial effects are seen only if  
therapy is started prior to inoculation or soon  
thereafter. 
 Nevertheless, antiviral therapy may be 
considered in acute, fulminant myocarditis, in 
institutional outbreaks and in laboratory-acquired 
cases 
Treatment: pathogenetic therapy 
Avoidance of exercise  
 Physical activity should be restricted to 
reduce the work of the heart during the 
acute phase of myocarditis, especially when 
there is fever, active systemic infection, or 
heart failure  
Terms of physical activity limitation 
• 10 – 14 days – mild myocarditis (up to ECG 
normalization) 
• 4 – 6 weeks – moderate myocarditis (up to 
normalization of heart size) 
• Individually – severe myocarditis (up to 
decreasing of HF severity and disappearance of 
rhythm disorders) 
Treatment: symptomatic 
 Treatment of systolic heart failure (ACEI/ARA, beta-
blockers, diuretics, aldosterone antagonists, digoxin 
in atrial fibrillation/flutter) 
 Treatment of arrhythmias (beta-blockers, 
amiodarone) 
 Anticoagulation to prevent thromboemboli (mural 
thrombi) – warfarin (INR 2,0 – 3,0) 
 NSAID – only for perimyocarditis with normal LV 
function and prominent chest pain from pericarditis. 
 Pacemaker for complete AV block 
 ? prednisone and azathioprine - no apparent benefit 
seen in the Myocarditis Treatment Trial 
Cardiomyopathies 
 The term `cardiomyopathy ' was first used in 
1957 by Brigden, who described a group of 
uncommon, non-coronary myocardial 
diseases 
 In 1961 Goodwin defined cardiomyopathies 
as ``myocardial diseases of unknown 
cause'‘. He described three different entities, 
namely ``dilated, hypertrophic and 
restrictive'', terms which are still in use 
today 
 Controversial classifications 
Cardiomyopathy 
Cardiomyopathy Classification  
Classification  (2 systems) 
• Based on Suspected Etiology 
 Primary -defined as those involving only the heart  
• may be genetic, mixed (genetic or non genetic), or 
acquired 
 Secondary -characterized by a generalized multiorgan 
involvement  
• which are accompanied by other organ system 
involvement 
World Health Organization and International Society and 
Federation of Cardiology classifiy on the basis of their 
pathologic or pathophysiologic features (more accepted 
system) – All are based off of echocardiography - 1980 year 3 
types: 
• Dilated – usually mostly Systolic dysfunction 
• Restrictive – usually mostly Diastolic dysfunction 
• Hypertrophic – usually mostly Diastolic dysfunction 
In 1996 World Health Organization and 
International Society and Federation of 
Cardiology added: 
 arrhythmogenic right ventricular dysplasia'' 
(with the inappropriate term ``dysplasia'' 
later changed to ``cardiomyopathy'') 
 a group of ``unclassified 
cardiomyopathies'', defined as ``those that 
do not fit in any group'' 
Cardiomyopathy Classification  
Definition of the cardiomyopathies  
European Society of Cardiology, 
2008 
``myocardial disorders in which the 
heart muscle is structurally and 
functionally abnormal in the absence 
of coronary artery disease, 
hypertension, valvular or congenital 
heart disease sufficient to cause the 
observed myocardial abnormality'' 
Groups of the cardiomyopathies  
European Society of Cardiology, 2008 
1. Hypertrophic 
2. Dilated 
3. Restrictive 
4. Arrhytmogenic right ventricular 
cardiomyopathy 
5. Unclassified 
• LV non-compaction 
• Takotsubo cardiomyopathy 
Cardiomyopathy 
 3rd most common form of heart 
disease in U.S. 
 2nd most common cause of 
adolescent sudden death 
(hyperthrophic obstructive 
cardiomyopathy) 
Hypertrophic cardiomyopathy 
(HCM) 
 
 HCM is a genetic disease characterized 
by unexplained LV hypertrophy, 
associated with non-dilated ventricular 
chambers, in the absence of another 
cardiac or systemic disease capable of 
producing that degree of hypertrophy 
Hypertrophic Cardiomyopathy 
 prevalence of hypertrophic cardiomyopathy in the 
absence of aortic valve disease or systemic 
hypertension is at least 1:500 of the adult population  
 Mortality 1%, 4-6% in childhood/adolescence  
 Sarcomeric gene mutations are the most frequent 
cause of HCM, accounting for approximately 30 - 65% 
of cases 
 A small proportion of patients with the HCM 
phenotype are affected by neuromuscular diseases 
(e.g. Frederich's ataxia), mitochondrial diseases, 
metabolic disorders of lysosomal storage diseases 
(i.e. Fabry, Pompe, Danon) 
Pedigree of a family with HCM which was 
described for the 1st time in 1957-1958yy. 
 
 
Brock RC. Functional obstruction of the left ventricle. Guy’s Hosp Rep 1957;106:221–38; Teare D. 
Asymmetrical hypertrophy of the heart in young adults. Br Heart J 1958;20:1–18. 
 
 
Hypertrophic cardiomyopathy; 
diagnostic criteria 
 HCM is diagnosed by a maximal LV wall 
thickness greater than 15 mm, based on 
echocardiography (ECHO) or cardiac 
magnetic resonance (CMR).  
 This value is lowered to 13 - 14 mm, when 
family members are screened. 
 Abnormal compliance-impaired diastolic 
relaxation and filling-output usually 
normal 
 
 
HCM: Echocardiographic and cardiac magnetic 
resonance images from a 17- year old female 
patient 
Parasternal long and short axis views show 
severe LV thickness values with redundant mitral 
leaflets and small cavity size. 
HCM: Echocardiographic and cardiac 
magnetic resonance images from a 17- 
year old female patient 
Apical 4 chambers view 
shows massive 
hypertrophy of the 
septum and the antero-
lateral wall 
 
The distribution of hypertrophy is 
usually asymmetric and sometimes 
confined to one or two LV segments.  
As a consequence, LV mass 
(measured by CMR) can be within the 
normal range. 
LV outflow tract obstruction is an 
important feature of HCM, and may be 
demonstrated in up to 70% patients 
HCM 
А. Massive 
hypertrophy of the 
septum 
В. Chaotic arrangement 
of of cardiomyocytes  
С. Wall thickening and 
narrowing of the 
coronary arteries 
(hematoxylin and eosin x50). Adapted from Maron BJ. 
Hypertrophic cardiomyopathy. Current Probl 
Cardiol. 1993;18:637-704 
Left ventricular outflow obstruction in HCM 
 
In early systole (bottom left), abnormal flow around the hypertrophied septum 
pushes the mitral valve into the outflow tract and results in obstruction and 
mitral valve regurgitation (bottom right).  
S R Ommen, P M Shah, A J Tajik Heart 2008;94:1276-1281  
Hypertrophic Cardiomyopathy 
 Presentation (HF diastolic, ischemia, 
arrhythmia) 
• Dyspnea on exertion,  
• ischemic chest pain 
• Palpitations, arrhythmias, syncope, pre-syncope 
• Sudden Death (usually due to V-tach during exercise) 
 Physical Exam 
• S4 gallop 
• prominent systolic ejection murmur at left sternal border that 
increases with valsalva, sudden standing, or exercise – in the 
presence of LV outflow obstruction) 
 
Hypertrophic Cardiomyopathy 
 Diagnosis 
• Chest Xray:  usually normal 
• Echocardiogram:  LVH with disproportionate 
septal hypertrophy; small ventricular volume 
• ECG:  LVH (30%) , & LAH ( 25-50%); Large 
septal Q waves-25%, Afib and PVCs common 
 * think hypertrophic cardiomyopathy in any 
young person whose EKG shows large 
septal Q waves* 
ECG in HCM 
Hypertrophic Cardiomyopathy 
 Treatment 
• Can become unstable in afib due to lack of 
atrial kick (cardioversion & heparinization) 
• Long term care with Beta blockers 
• Amiodarone is treatment of choice for 
ventricular dysrhythmias 
• Diuretics in the face of pulmonary congestion 
• Avoid agents that reduce ventricular volume 
(nitrates) or increase myocardial contractility 
(digoxin) 
• Antibiotic prophylaxis for dental procedures  
• Avoidance of competitive athletics 
• Anticoagulation if in afib 
Dilated cardiomyopathy (DCM) 
DCM is characterized by LV dilatation 
and global systolic dysfunction (EF < 
50%), in the absence of coronary 
artery disease or other identifiable 
causes (such as systemic 
hypertension, valve disease,drugs, 
inflammatory heart diseases) 
capable of causing that magnitude of 
impairment 
Dilated Cardiomyopathy 
 
 incidence - 5 to 8 cases per 100,000 
population 
 prevalence of 36 per 100,000 
 African Americans and males have 2.5x 
increased risk 
 Most common age of diagnosis 20-50yrs 
 80% of DCM cases are idiopathic 
Dilated Cardiomyopathy 
Clinical Presentation: symptoms 
Usually presents as unexplained heart 
failure (prior to echo)  
 Symptoms of CHF-dyspnea on 
exertion, orthopnea and paroxysmal 
nocturnal dyspnoe. 
 Chest pain can occur due to low 
coronary vascular reserve 
 Palpitations  
 
 
 
Dilated Cardiomyopathy 
Clinical Presentation: Signs 
 
 Rales, S3 S4 gallops, narrow pulse 
pressure, murmurs of mitral or tricuspid 
regurgitation  
 Manifestations of embolizaiton neurologic  
deficits, flank pain, hematuria, pulseless  
cyanotic extremity  
 
 
 
Dilated Cardiomyopathy 
Diagnosis 
 Holosystolic regurgitant murmur or gallop may be 
present 
 Dependent edema, bibasilar rales 
 CXR- enlarged heart, biventricular enlargement, 
and pulmonary vascular congestion  
 ECG- LVH, Left atrial enlargement, Q waves, poor 
R wave progression, afib 
 Echo-Confirms Dx.- Dilation of all four chambers 
(ventricles greater than atria); increased muscle 
mass; systolic failure - increased systolic and 
diastolic volumes, decreased EF, valvular 
regurgitation (relative valvular insufficiency); 
mural thrombi  
 
Heart chambers 
dilatation in DCM 
Dilated Cardiomyopathy 
Treatment 
 HF - ACE inhibitors and B-Blockers-
improve survival;  
 Amiodarone- for complex venticular 
ectopy 
 Anticoagulation can be considered: 
all with mural thrombi; evidence of 
pulmonary or systemic emboli; atrial 
fibrillation 
 
 RCM is defined by the presence of a 
restrictive LV physiology, with 
normal or more often reduced 
diastolic/systolic volumes, normal 
wall thickness and systolic function, 
marked diastolic flow impairment 
and biatrial dilatation.  
Restrictive Cardiomyopathy (RCM) 
Restrictive Cardiomyopathy 
(amyloidosis) 
 
 LV normal wall 
thickenness and 
small cavities  
Restrictive Cardiomyopathy 
 
 RCM are rather uncommon, although 
their prevalence is still unknown. 
 Mostly idiopathic- sometimes familial 
 Systemic disorders-amyloidosis, 
sarcoidosis, hemochromatosis, 
scleroderma, and carcinoid. 
 
Restrictive Cardiomyopathy 
Clinical Features 
 Symptoms of CHF-dyspnea, 
orthopnea, pedal edema- rare chest 
pain 
 Exam-may have S3 or S4 gallop, 
regurgitation murmurs, rales, jugular 
vein distension, Kussmaul’s sign (jvd 
with inspiration), hepatomegaly, pedal 
edema or ascites 
Restrictive Cardiomyopathy 
Diagnosis 
 CXR-signs of CHF without cardiomegaly 
 ECG-nonspecific changes most likely 
 Conduction disturbances and low-voltage 
QRS complexes are common with 
amyloidosis or sarcoidosis 
 Ultrasound - Low end diastolic volume; 
Decreased cardiac output; markedly 
dilated atria, normal systolic function, 
mitral/tricuspid regurgitation 
Restrictive Cardiomyopathy: Treatment 
 
 Symptom directed-diuretics and ACE 
inhibitors 
 Corticosteroids for sarcoidosis 
 Chelation therapy for 
hematochromatosis 
Arhythmogenic Right Ventricular 
Cardiomyopathy (ARVC) 
 ARVC is 
characterized by 
fibrofatty 
replacement of the 
right ventricular 
myocardium and 
ventricular 
arrhythmias 
Arhythmogenic Right Ventricular 
Cardiomyopathy (ARVC) 
 Most rare form of cardiomyopathy 
 Ventricular arrhythmias are the clinical 
hallmark of the disease, but atrial 
fibrillation may also occur. 
 Major cause of SCD in young, especially in 
some regions of Italy, still exists in US - 
consider in young pt with syncope, 
palpitations, and aborted SCD 
 Typical presentation of sudden death in 
young or middle aged pt 
 Familial in 50% of cases 
Arhythmogenic Right Ventricular 
Cardiomyopathy (ARVC) 
ARVC is generally a 
familial disease with 
autosomal dominant 
inheritance but it 
may be recessive 
when associated 
with woolly 
hair and 
palmopalmar 
hyperkeratosis (eg, 
Naxos disease, 
Carvajal syndrome) 
 Exam usually normal 
 ECG- inverted T waves from V1 to V4, RBBB and 
isolated premature ventricular beats with an LBBB 
morphology may be present 
 Echo-necessary for diagnosis: 
• In the most common right-dominant form, 
structural changes may be absent or confined to a 
localized region of the right ventricle (inflow and 
outflow tract, right ventricular apex, known as the 
`triangle of dysplasia') at an early stage 
 
Arhythmogenic Right Ventricular 
Cardiomyopathy (ARVC) 
Twelve lead ECG : inverted T waves from V1 to V4 and 
isolated premature ventricular beats with an LBBB 
morphology 
 
Echocardiographic image of ARVC 
evident systolic 
bulging in 
infundibular, 
apical, and 
subtricuspid 
regions of the RV 
(`triangle of dysplasia')  
CMR images of ARVC 
wall aneurysms 
within the `triangle 
of dysplasia’ 
ARVC: Treatment 
 β blockers and class I and III 
antiarrhythmic drugs  
 catheter ablation 
 implantable cardioverter defibrillator 
(ICD).  
Tako-Tsubo cardiomyopathy 
 LV apical ballooning after a high 
catecholamine stress which results in 
LV shape similar to octopus pot 
(takotsubo pot which is Japanese 
octopus trap) 
 Has been described following 
stressful event like hypoglycemia, 
earthquakes, following surgery, after 
emotional stress  
Tako-Tsubo cardiomyopathy 
Tako-Tsubo cardiomyopathy: 
clinical features 
 Presents as acute anterior MI with 
chest pain or SOB 
 Usually in post-menopausal women 
 Cardiac catheterization reveals clean 
coronary arteries 
 Prognosis is good unless there is 
serious complication (like MR, 
ventricular rupture, v-tachycardia) 
 
Tako-Tsubo cardiomyopathy: 
treatment 
 Preventing of  excessive sympathetic 
activation by combining alpha and beta 
blockade.  
 Beta blockers are used to treat dynamic 
left ventricular obstruction.  
 Phenylephrine may represent an 
alternative approach in patients 
presenting with outflow tract obstruction 
and severe hypotension.  
 In hemodynamically unstable patients, 
early administration of intra-aortic balloon 
pump counterpulsation should be 
considered  
Isolated LV non-compaction (LVNC)  
 is characterized by prominent LV trabeculae and 
deep inter-trabecular recesses, that can be 
associated with LV dilatation and systolic 
dysfunction 
 Congenital disorder  
 Can be isolated or occur with other congenital 
heart diseases 
 Facial abnormalities and neurologic problems 
also occur in high proportion of pts with LVNC 
 Some genetic links, screen 1st degree relatives 
Isolated LV non-compaction 
(LVNC) 
 Multiple 
trabeculations and 
recesses are 
evident, 
particularly in the 
apex and the free 
wall of the LV 
 
Isolated LV non-compaction 
(LVNC) 
 CMR confirmed the diagnosis: Multiple 
trabeculations and recesses  
Treatment of LVNC 
Treatment of: 
 HF 
 Rhythm abnormalities 
